Europe Pulmonary Arterial Hypertension Market

The Europe pulmonary arterial hypertension market is expected to grow from US$ 1,959.47 million in 2022 to US$ 2,683.07 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.

Growing Incidence of Pulmonary Arterial Hypertension Drives Europe Pulmonary Arterial Hypertension Market

Pulmonary arterial hypertension (PAH) affects the tiny arteries in the lung, making it thick and narrow and blocking the blood flow through the lungs. As a result, blood pressure in the lungs increases, and the heart faces difficulties in pumping blood through narrowed arteries. Over time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women between the ages of 30 and 60. Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 7.6 cases per million in Scotland. Idiopathic PAH—in which a family history or an identified risk factor is present—is even rare, recording 2.6 cases per million in Scotland. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the Europe pulmonary arterial hypertension market.

Europe Pulmonary Arterial Hypertension Market Overview

The Europe pulmonary arterial hypertension market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the global pulmonary arterial hypertension market. The Europe pulmonary arterial hypertension market is expected to witness significant growth during the forecast period due to a rise in product approvals. Pulmonary hypertension is a rare condition that affects approximately one in 20,000 people in the UK. In 2021, 7,876 individuals in the UK suffered from pulmonary hypertension. In the UK, younger patients suffering from idiopathic pulmonary arterial hypertension (IPAH) have a 5-year survival above 80%. In the UK, patients suffering from PAH and CTEPH (the disease is caused due to a direct consequence of changes in the pulmonary vasculature) are most commonly treated in nine specialist centers across the country. The Pulmonary Hypertension Association UK (PHA-UK) in the UK advocates exclusively for people affected by pulmonary hypertension. Therefore, such initiatives are expected to fuel the pulmonary arterial hypertension drug market in the country during the forecast period.

Europe Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Europe Pulmonary Arterial Hypertension Strategic Insights

Strategic insights for the Europe Pulmonary Arterial Hypertension provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Pulmonary Arterial Hypertension Report Scope

Europe Pulmonary Arterial Hypertension Regional Insights

The geographic scope of the Europe Pulmonary Arterial Hypertension refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Europe pulmonary arterial hypertension market.

Based on route of administration, the Europe pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Europe pulmonary arterial hypertension market.

Based on country, the Europe pulmonary arterial hypertension market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and United Therapeutics Corp are the leading companies operating in the Europe pulmonary arterial hypertension market.